{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T09:40:58Z","timestamp":1773999658377,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003968","name":"Iran National Science Foundation","doi-asserted-by":"publisher","award":["4027319"],"award-info":[{"award-number":["4027319"]}],"id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022299","name":"School of Medicine, Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022299","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","award":["43009080"],"award-info":[{"award-number":["43009080"]}],"id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Analytical Biochemistry"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ab.2026.116067","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:57:34Z","timestamp":1769533054000},"page":"116067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Production and characterization of novel murine monoclonal antibodies against programmed death-ligand 1 with potential diagnostic application in immunohistochemistry"],"prefix":"10.1016","volume":"712","author":[{"given":"Mansoure","family":"Mansouri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Montazer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra Sadat","family":"Faghih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Soltanshahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fazel","family":"Shokri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmood","family":"Jeddi-Tehrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7084-5709","authenticated-orcid":false,"given":"Mahdi","family":"Shabani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ab.2026.116067_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"7528","key":"10.1016\/j.ab.2026.116067_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ab.2026.116067_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/PAI.0000000000000594","article-title":"Development of a PD-L1 complementary diagnostic immunohistochemistry assay (SP142) for atezolizumab","volume":"27","author":"Vennapusa","year":"2019","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.ab.2026.116067_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13000-021-01151-x","article-title":"PD\u2212 L1 immunostaining: what pathologists need to know","volume":"16","author":"Akhtar","year":"2021","journal-title":"Diagn. Pathol."},{"issue":"1","key":"10.1016\/j.ab.2026.116067_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ab.2026.116067_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"28","key":"10.1016\/j.ab.2026.116067_bib7","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non\u2012small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ab.2026.116067_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0382-2","article-title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)","volume":"6","author":"Brahmer","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.ab.2026.116067_bib9","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ab.2026.116067_bib10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5306\/wjco.v5.i3.382","article-title":"Significance of immunohistochemistry in breast cancer","volume":"5","author":"Zaha","year":"2014","journal-title":"World J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ab.2026.116067_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/MCP.0000000000001034","article-title":"Practical challenges in lung cancer pathology: bedside care to treatment decisions","volume":"30","author":"Takano","year":"2024","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"4","key":"10.1016\/j.ab.2026.116067_bib12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/hyb.2011.0023","article-title":"Characterization of novel murine monoclonal antibodies directed against the extracellular domain of human HER2 tyrosine kinase receptor","volume":"30","author":"Kazemi","year":"2011","journal-title":"Hybridoma"},{"key":"10.1016\/j.ab.2026.116067_bib13","article-title":"Correlation between estrogen receptor and programmed death ligand-1 in type I endometrial cancer","volume":"21","author":"Waluyo","year":"2024","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol. X"},{"issue":"4","key":"10.1016\/j.ab.2026.116067_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/86297","article-title":"A fresh look at tumor immunosurveillance and immunotherapy","volume":"2","author":"Smyth","year":"2001","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.ab.2026.116067_bib16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.ab.2026.116067_bib17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ab.2026.116067_bib18","article-title":"Discovery of anti-PD-L1 human domain antibodies for cancer immunotherapy","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ab.2026.116067_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/annonc\/mdx755","article-title":"Comprehensive analysis of the clinical immuno-oncology landscape","volume":"29","author":"Tang","year":"2018","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ab.2026.116067_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/cancers10020032","article-title":"Tackling cancer resistance by immunotherapy: updated clinical impact and safety of PD-1\/PD-L1 inhibitors","volume":"10","author":"Abdin","year":"2018","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ab.2026.116067_bib21","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1038\/s41598-020-60950-2","article-title":"Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study","volume":"10","author":"Tsimafeyeu","year":"2020","journal-title":"Sci. Rep."},{"issue":"Suppl 2","key":"10.1016\/j.ab.2026.116067_bib22","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.4103\/0975-7406.100281","article-title":"Applications of immunohistochemistry","volume":"4","author":"Duraiyan","year":"2012","journal-title":"J. Pharm. BioAllied Sci."},{"issue":"19","key":"10.1016\/j.ab.2026.116067_bib23","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti\u2013programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ab.2026.116067_bib24","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0006-291X(03)01257-9","article-title":"Differential binding properties of B7-H1 and B7-DC to programmed death-1","volume":"307","author":"Youngnak","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.ab.2026.116067_bib25","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1078-0432.CCR-12-2063","article-title":"Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer","volume":"19","author":"Sznol","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ab.2026.116067_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.acthis.2006.01.003","article-title":"Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance","volume":"108","author":"Wu","year":"2006","journal-title":"Acta Histochem."},{"issue":"8","key":"10.1016\/j.ab.2026.116067_bib28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/PAI.0000000000000256","article-title":"Development of an automated PD-L1 immunohistochemistry (IHC) assay for non\u2013small cell lung cancer","volume":"23","author":"Phillips","year":"2015","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"11","key":"10.1016\/j.ab.2026.116067_bib29","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.5858\/arpa.2015-0544-OA","article-title":"Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue","volume":"140","author":"Dolled-Filhart","year":"2016","journal-title":"Arch. Pathol. Lab Med."},{"issue":"1","key":"10.1016\/j.ab.2026.116067_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s43856-022-00206-4","article-title":"Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer","volume":"2","author":"Song","year":"2022","journal-title":"Commun. Med."},{"issue":"2","key":"10.1016\/j.ab.2026.116067_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/PAI.0000000000000531","article-title":"Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1 (PD-L1) on non\u2013small cell lung carcinoma","volume":"26","author":"Parra","year":"2018","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"7","key":"10.1016\/j.ab.2026.116067_bib32","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3390\/cancers16071356","article-title":"PD-L1 expression in high-risk non-muscle-invasive bladder cancer is influenced by intravesical bacillus calmette\u2013Gu\u00e9rin (BCG) therapy","volume":"16","author":"Maas","year":"2024","journal-title":"Cancers"}],"container-title":["Analytical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269726000230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269726000230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T06:16:38Z","timestamp":1773987398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003269726000230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":30,"alternative-id":["S0003269726000230"],"URL":"https:\/\/doi.org\/10.1016\/j.ab.2026.116067","relation":{},"ISSN":["0003-2697"],"issn-type":[{"value":"0003-2697","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Production and characterization of novel murine monoclonal antibodies against programmed death-ligand 1 with potential diagnostic application in immunohistochemistry","name":"articletitle","label":"Article Title"},{"value":"Analytical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ab.2026.116067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116067"}}